Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis

Simple item page
dc.contributor.authorUslu S.
dc.contributor.authorGülle S.
dc.contributor.authorSen G.
dc.contributor.authorCapar S.
dc.contributor.authorSenel S.
dc.contributor.authorDalkılıc E.
dc.contributor.authorAkar S.
dc.contributor.authorKoca S.S.
dc.contributor.authorTufan A.
dc.contributor.authorYazici A.
dc.contributor.authorYilmaz S.
dc.contributor.authorInanc N.
dc.contributor.authorBirlik M.
dc.contributor.authorSolmaz D.
dc.contributor.authorCefle A.
dc.contributor.authorGoker B.
dc.contributor.authorDireskeneli H.
dc.contributor.authorYolbas S.
dc.contributor.authorSteen Krogh N.
dc.contributor.authorYilmaz N.
dc.contributor.authorErten S.
dc.contributor.authorBes C.
dc.contributor.authorSoysal Gündüz O.
dc.contributor.authorOztürk M.A.
dc.contributor.authorHaznedaroglu S.
dc.contributor.authorYavuz S.
dc.contributor.authorOnen F.
dc.contributor.authorSari I.
dc.date.accessioned2025-04-10T11:01:55Z
dc.date.available2025-04-10T11:01:55Z
dc.date.issued2024
dc.description.abstractBackground/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice. Methods: We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (≥2nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated. Results: There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 ± 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and ≥second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20/40 response rates at three and six months. Nonetheless, both groups’ response rates at one year were comparable. Conclusions: In this real-world data analysis, AS patients who were TNFi naïve (1st-line) and subsequently treated (≥2nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety. © 2024 by the authors.
dc.identifier.DOI-ID10.3390/jcm13237266
dc.identifier.urihttp://hdl.handle.net/20.500.14701/43704
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.titleEfficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu